Near-term overhang for Alkem Laboratories' fast growing US business
Any adverse outcome of the FDA's observations will impact the company's overall growth04-04-2018
04-04-2018
Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
As per the requirement of Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both, physical and electronic share transfer facility for Alkem Laboratories Limited (hereinafter referred to as 'the Company') are maintained during the period from 1st October, 2017 to 31st March, 2018 (both days inclusive) by the Company's Registrar and Share Transfer Agent,...03-04-2018
Alkem Labs gets 14 USFDA observations
Alkem Laboratories has said the US Food and Drug Administration (USFDA) has pointed out 14 observations for objectionable conditions at its manufacturing units at Amaliya in Daman and St Louis in28-03-2018
Board Meeting-Closure of Trading Window
This is to inform you that in terms of Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 30th March, 2018 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and year ended 31st March, 2018 are communicated to the Stock Exchanges.28-03-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that the US FDA had conducted an inspection at the Company's manufacturing facility located at Amaliya, Daman, India from 19th March, 2018 to 27th March, 2018. Post the inspection, the Company has received a Form 483 with thirteen observations. The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA observations and the same is proposed to be filed within the timeline stipulated by the US FDA....28-03-2018
Is Tiger Balm set for a big leap in India with Alkem as its rider?
Legacy brand, Tiger Balm, is overhauling its image and positioning in a new alliance with the pharmaceutical major26-02-2018
Stempeutics ink outlicensing deal with Alkem for osteoarthritis drug
Banglaore-based Stempeutics Research, a group company of Manipal Education and Medical Group (MEMG), has signed an out-licensing deal with Alkem Laboratories, Mumbai for a potential osteoarthritis knee therapy Stempeucel.11-02-2018
Board Meeting-Closure of Trading Window
Intimation of Opening of Trading Window We refer to our earlier communication dated 26th December, 2017 regarding closure of trading window (for the purpose of financial results for the quarter and nine months ended 31st December, 2017) starting from 30th December, 2017 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and nine months ended 31st December, 2017 are communicated to the Stock Exchanges....09-02-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith press release and analyst presentation on Q3FY18 and 9MFY18 earnings and business updates and the same will be uploaded on the website of the Company. Kindly take note of the same.09-02-2018
Corporate Action-Board approves Dividend
The Board of Directors of the Company, at its meeting held today, i.e. 9th February, 2018 inter alia, has Declared Interim Dividend of Rs. 6/- (Rupees Six only) per equity share on the face value of Rs. 2/- per share for the financial year 2017-18 pursuant to Regulation 43 read with Regulation 30 of the Listing Regulations. The date of payment of Interim Dividend shall be on and from 23rd February, 2018....09-02-2018